An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Allergan
ClinicalTrials.gov Identifier:
NCT01608659
First received: May 29, 2012
Last updated: June 25, 2012
Last verified: June 2012

May 29, 2012
June 25, 2012
April 2011
June 2011   (final data collection date for primary outcome measure)
Average Total Dose Per Treatment Period [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
Average total dose per treatment period was defined as total treatment dose plus total touch-up dose plus total follow-up dose.
Average Total Dose per Treatment Cycle [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01608659 on ClinicalTrials.gov Archive Site
  • Inter-Injection Interval Duration of Each Treatment Period [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
    Inter-injection interval duration of each treatment period. Duration is defined as the number of days of an injection cycle.
  • Percent of Subjects Reporting Satisfaction With Treatment Effects [ Time Frame: 24 Months ] [ Designated as safety issue: No ]
    Percent of subjects reporting satisfaction with treatment effects per chart notes.
  • Inter-Injection Intervals Between Treatment Cycles [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
  • Percent of Subjects Reporting Satisfaction with Treatment Effects [ Time Frame: 12 Months ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
An Observational Retrospective Study to Evaluate Treatment Patterns of Botulinum Toxin Type A
Not Provided

This is a retrospective chart review to evaluate treatment patterns of botulinum toxin Type A for the treatment of facial lines.

Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Subjects treated for glabellar lines (hyperfunctional facial lines) with botulinum toxin Type A

Facial Rhytides
Drug: botulinum toxin Type A
Previous treatment with botulinum toxin Type A for treatment of facial lines
Other Names:
  • BOTOX®
  • Xeomin®
botulinum toxin Type A
Previous treatment with botulinum toxin Type A for treatment of facial lines
Intervention: Drug: botulinum toxin Type A
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
110
June 2011
June 2011   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Previously treated for glabellar lines (hyperfunctional facial lines) with botulinum toxin Type A preparation
  • Received 2 treatment cycles wtih botulinum toxin Type A (BOTOX®) prior to at least 1 treatment with botulinum toxin Type A (Xeomin®)

Exclusion Criteria:

  • None
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Argentina
 
NCT01608659
GMA-BTXC-10-001
No
Allergan
Allergan
Not Provided
Study Director: Medical Director Allergan
Allergan
June 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP